Pfizer's Zoetis IPO could raise $2.2B

Closing in on its IPO for its animal health unit Zoetis, Pfizer ($PFE) on Thursday reported that it would price shares between $22 and $25 each, potentially raising $2.2 billion when it happens at the end of the month, Bloomberg reports. The company intends to offer 86.1 million shares, a 20% stake, to investors. Article


Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.